reports
Moody’s Ratings affirms Swiss Re Corporate Solutions Brasil Seguros’ B...
New York , May 3, 2024 – Moody's Ratings (Moody's) has affirmed the Baa3 global scale insurance financial strength (IFS) rating of Swiss Re Corporate Solutions Brasil Seguros S.A. (SRCSB). The rating outlook for SRCSB was changed to positive from stable. The rating action follows Moody's announcemen...
Taitron Announces Quarterly Cash Dividend
Taitron Announces Quarterly Cash Dividend LOS ANGELES, May 03, 2024 (GLOBE NEWSWIRE) -- Taitron Components Incorporated (NASDAQ:TAIT) today announced that its Board of Directors has declared a quarterly cash dividend of $0.05 per share of common stock, payable on May 31, 2024 to stockholders of record as of the close of business on May 17, 2024. Under our current dividend policy, the Company will target a cash dividend to our stockholders in the amount of $0.20 per share per annum, payable in equal $0.05 per share quarterly installments. Subsequent dividend declarations and the establish...
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(...
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company’s SVP, Engineering, Regulatory, and Compliance; the Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Melnikoff in connection with the commencement of his employment. The RSUs were granted as an inducemen...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under N...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2024 an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer, under the terms of the 2022 Employment Inducement Award Plan, a...
Bel Fuse Announces Upcoming Investor Conference Schedule for May 2024
Bel Fuse Announces Upcoming Investor Conference Schedule for May 2024 WEST ORANGE, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- Bel Fuse Inc. (Nasdaq: BELFA and BELFB), a leading global manufacturer of products that power, protect and connect electronic circuits, today announced its investor conference schedule for May 2024: Oppenheimer 19th Annual Industrial Growth Conference (Virtual)Farouq Tuweiq, CFOLynn Hutkin, VP Financial Reporting & Investor RelationsTuesday, May 7, 2024Conducting meetings throughout the day with a presentation at 1:30 pm ET Cowen 52nd Annual Technology, Media & Telec...
Kernel Group Holdings, Inc. Extends Period to Consummate Initial Busin...
Kernel Group Holdings, Inc. Extends Period to Consummate Initial Business Combination New York, May 03, 2024 (GLOBE NEWSWIRE) -- Kernel Group Holdings, Inc. (NASDAQ: KRNLU, KRNL, KRNLW) (“KRNL” or the “Company”), a special purpose acquisition company, announced today that it has elected to extend the period of time it has to consummate its initial business combination by one month from May 5, 2024 to June 5, 2024 (the “Extension”). The Extension is the fourth of six-monthly extensions permitted under the Company’s governing documents. Cautionary Statement Regarding Forward-Looking Stat...
KLDiscovery Inc. to Report First Quarter 2024 Financial Results on May...
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- KLDiscovery Inc. (“KLD”), a leading global provider of electronic discovery, information governance and data recovery technology solutions will announce first quarter 2024 financial results following the market close on Wednesday, May 8, 2024. Management will conduct a conference call to discuss KLD’s financial results at 8:30 AM ET on Thursday, May 9, 2024. To participate in the conference call, please register via the following link: Once registered, you will receive an email with Direct Entry and Registrant ID along with dial-in details. To listen...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 528,000 shares of the Company's common stock in connection with their emp...
Aileron Therapeutics Announces Closing of Underwritten Registered Dire...
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announ...
Tennant Company Announces Senior Leadership Updates to Direct ERP Tran...
MINNEAPOLIS--(BUSINESS WIRE)-- (NYSE: TNC), a world leader in the design, manufacture and marketing of solutions that help create a cleaner, safer, healthier world, today announced it has made changes to its senior leadership team to support its enterprise growth strategy. Barb Balinski will provide dedicated executive oversight to the Company’s business process transformation initiative as the Company’s Senior Vice President, Chief Transformation Officer; Pat Schottler will move into a new role focused on product innovation and disruptive technologies as the Company’s Senior Vice President, ...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika...
S Split Corp. Declares Monthly Distribution
S Split Corp. Declares Monthly Distribution TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- (TSX: SBN; SBN.PR.A) S Split Corp. has declared monthly distributions, payable on May 31, 2024 to shareholders of record on May 15, 2024. Due to the decline in the net asset value (“NAV”) per unit below $16.50, the Company has suspended distributions on its Class A Shares in accordance with the Articles of Incorporation. The NAV per Unit on April 30, 2024 was $12.03. Share ClassTicker Amount Per ShareClass A SharesSBN$0.00000Preferred SharesSBN.PR.A$0.04375 To the extent that any portions of the d...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rul...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, the Netherlands and MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Dir...
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 47,625 shares of Vor Bio’s common stock to six newly hired employees. The foregoing stock options and RSUs were grant...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Ru...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees rece...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 563...
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass and DUBLIN, May 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on May 1, the Company granted to three newly hired employees (i) non-statutory stock options to purchase an aggregate of 20,150 ordina...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 160,500 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 117,000 shares of Arcutis’ common stock to 13 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted und...
Moody's Ratings affirms IPAB's ratings, outlook stable
Moody's Ratings (Moody's) has today affirmed Instituto para la Protección al Ahorro Bancario's (IPAB) Baa2 and Prime-2 long- and short-term issuer rating in local and foreign currency. The outlook of the IPAB remains stable in line with the stable outlook on the Government of Mexico (Baa2 stable). ...
Moody's Ratings upgrades ratings on two classes of CLO notes issued by...
Moody's Ratings (Moody's) has upgraded the ratings on the following notes issued by OZLM VIII, LTD.: U.S.$29,100,000 Class B-R3 Senior Secured Deferrable Floating Rate Notes due 2029 (the "Class B-R3 Notes"), Upgraded to Aaa (sf); previously on June 9, 2023 Upgraded to Aa1 (sf) U.S.$36,900,000 Class...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.